Health Catalyst (NASDAQ:HCAT - Free Report) had its price target trimmed by Stifel Nicolaus from $10.00 to $5.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a hold rating on the stock.
HCAT has been the subject of several other research reports. Royal Bank of Canada lowered their price objective on Health Catalyst from $9.00 to $7.00 and set a "sector perform" rating for the company in a research report on Wednesday, January 15th. Wells Fargo & Company reduced their price objective on Health Catalyst from $13.00 to $10.00 and set an "overweight" rating for the company in a report on Tuesday, January 21st. Piper Sandler reduced their price target on shares of Health Catalyst from $12.00 to $8.00 and set an "overweight" rating for the company in a research report on Tuesday, February 11th. Stephens restated an "equal weight" rating and set a $7.00 target price on shares of Health Catalyst in a research note on Thursday. Finally, Canaccord Genuity Group lowered their target price on shares of Health Catalyst from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, January 21st. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $9.45.
Read Our Latest Stock Report on Health Catalyst
Health Catalyst Trading Down 1.5 %
Shares of NASDAQ:HCAT traded down $0.07 on Thursday, hitting $4.60. The company had a trading volume of 1,833,303 shares, compared to its average volume of 869,545. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst has a 1 year low of $3.76 and a 1 year high of $9.24. The firm's 50-day simple moving average is $5.98 and its two-hundred day simple moving average is $7.24. The firm has a market capitalization of $279.90 million, a price-to-earnings ratio of -3.41 and a beta of 1.34.
Insider Buying and Selling at Health Catalyst
In related news, General Counsel Benjamin Landry sold 19,268 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $8.32, for a total transaction of $160,309.76. Following the completion of the sale, the general counsel now owns 72,250 shares of the company's stock, valued at $601,120. This represents a 21.05 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Linda Llewelyn sold 6,441 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $5.43, for a total value of $34,974.63. Following the completion of the sale, the insider now owns 85,819 shares of the company's stock, valued at approximately $465,997.17. This trade represents a 6.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 80,110 shares of company stock worth $596,993 over the last 90 days. Company insiders own 2.50% of the company's stock.
Hedge Funds Weigh In On Health Catalyst
Hedge funds have recently made changes to their positions in the company. Harbor Capital Advisors Inc. boosted its stake in shares of Health Catalyst by 21.3% in the third quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company's stock worth $96,000 after buying an additional 2,064 shares during the last quarter. Group One Trading LLC grew its holdings in shares of Health Catalyst by 107.6% in the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company's stock valued at $31,000 after purchasing an additional 2,260 shares during the period. Creative Planning grew its position in Health Catalyst by 13.2% in the third quarter. Creative Planning now owns 21,348 shares of the company's stock worth $174,000 after acquiring an additional 2,486 shares during the period. Two Sigma Securities LLC boosted its stake in Health Catalyst by 19.5% during the fourth quarter. Two Sigma Securities LLC now owns 17,510 shares of the company's stock worth $124,000 after buying an additional 2,862 shares during the period. Finally, Legato Capital Management LLC grew its position in Health Catalyst by 3.7% in the 4th quarter. Legato Capital Management LLC now owns 87,992 shares of the company's stock valued at $622,000 after acquiring an additional 3,171 shares in the last quarter. 85.00% of the stock is owned by institutional investors and hedge funds.
About Health Catalyst
(
Get Free Report)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
Further Reading
Before you consider Health Catalyst, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Health Catalyst wasn't on the list.
While Health Catalyst currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
